drugset / Trial / NCT02864264

Single Ascending Dose and Multiple Ascending Dose Study in Healthy Participants and Proof of Mechanism Study in Patients With Ulcerative Colitis

NCT02864264 ↗

Phase 1 Terminated 7 enrolled Bristol-Myers Squibb
RandomizedParallel-groupDouble-blindScreening

Summary

The primary purpose of this study is to determine if single and multiple doses of BMS-986184 are safe and well tolerated in healthy male and female subjects. The primary purpose of the proof of mechanism study is to determine safety and efficacy in patients with ulcerative colitis.

Timeline

Start
2016-09-14
Primary completion
2017-09-27
Completion
2017-09-27

Outcome

Outcome not reported

Stopped: “Adverse change in the risk/benefit”

Drugs

EvaluationDrugModalityDoseRoute
Subject BMS-986184 Unknown — Intravenous

Indications